Patents by Inventor Roberto Pellicciari

Roberto Pellicciari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Farnesoid X receptor modulators
    Patent number: 11034717
    Abstract: The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 15, 2021
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Farnesoid x receptor modulators
    Patent number: 11000532
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 11, 2021
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20210122779
    Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: September 2, 2020
    Publication date: April 29, 2021
    Inventors: Roberto PELLICCIARI, Antimo GIOIELLO, Antonio MACCHIARULO, Francoise PERRON-SIERRA, Klaus SEEDORF
  • Treatment of fibrosis using FXR ligands
    Patent number: 10987362
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 27, 2021
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20210101927
    Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 8, 2021
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • TREATMENT OF FIBROSIS USING FXR LIGANDS
    Publication number: 20200397803
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 24, 2020
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • 3-desoxy derivative and pharmaceutical compositions thereof
    Patent number: 10815267
    Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 27, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • TGR5 modulators and methods of use thereof
    Patent number: 10800807
    Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: October 13, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
  • FARNESOID X RECEPTOR MODULATORS
    Publication number: 20200297739
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Application
    Filed: November 26, 2019
    Publication date: September 24, 2020
    Inventor: Roberto Pellicciari
  • INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
    Publication number: 20200207721
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: October 31, 2019
    Publication date: July 2, 2020
    Inventors: Roberto PELLICCIARI, Johan AUWERX, Nadia RAFFAELLI
  • Farnesoid X receptor modulators
    Patent number: 10532061
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 14, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
    Patent number: 10513499
    Abstract: The present disclosure discloses compounds capable of modulating the activity of ?-amino-?-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: December 24, 2019
    Assignee: TES Pharma S.r.l.
    Inventors: Roberto Pellicciari, Johan Auwerx, Nadia Raffaelli
  • STEROIDS AS AGONISTS FOR FXR
    Publication number: 20190300564
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Application
    Filed: July 10, 2017
    Publication date: October 3, 2019
    Inventor: Roberto Pellicciari
  • Steroids as agonists for FXR
    Patent number: 10421772
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 24, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • TGR5 MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20190284225
    Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: June 16, 2016
    Publication date: September 19, 2019
    Inventors: Roberto PELLICCIARI, Antimo GIOIELLO, Antonio MACCHIARULO
  • Methods for preparation of bile acids and derivatives thereof
    Patent number: 10414791
    Abstract: The present application relates to a method of preparing compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, R1 is H, ?-OH, ?-OH, or an oxo group.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: September 17, 2019
    Assignee: Intercept Pharmaceuticals, Inc
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • FARNESOID X RECEPTOR MODULATORS
    Publication number: 20190209586
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Application
    Filed: September 6, 2018
    Publication date: July 11, 2019
    Inventor: Roberto Pellicciari
  • Treatment of fibrosis using FXR ligands
    Patent number: 10258633
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 16, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • Process for preparing bile acid derivatives
    Patent number: 10202414
    Abstract: The present invention relates to processes for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed bond (----) at position 7 indicates that the substituent is in an ? or ? stereochemistry; R is hydrogen or hydroxy; and R1 is hydrogen or C1-C6 alkyl
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioello
  • Steroids as agonists for FXR
    Patent number: RE48286
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: October 27, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari